Wiesław Bonicki
Research Subjects
Research Interests
Wiesław Bonicki has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Radosław Michalik
4 shared publications- Paweł Nauman
Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland
3 shared publications Andrzej Kukwa
2 shared publicationsArtur Oziębło
2 shared publications- Jacek Kunicki
Department of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2 shared publications Romuald Krajewski
2 shared publications
Latest Publications
- 1 January 2012
- Published by VM Media Group sp. z o.o in Neurologia i Neurochirurgia Polska
- Vol. 46 (5) , 428-435
Motor cortex stimulation in the treatment of neuropathic pain
Despite the rapid development of neuropharmacotherapy, medical treatment of neuropathic pain (NP) still constitutes a significant socioeconomic problem. The authors herein present a group of patients treated with motor cortex stimulation (MCS) for NP of various types and aetiologies. Our cohort included 12 female and 11 male NP patients aged 53 ± 16 treated with MCS. Eleven patients were diagnosed with neuropathic facial pain (NFP), 8 with hemi-body neuropathic pain (HNP), and 4 with deafferentation pain (DP). Prior to surgery, 16 out of 23 patients were treated with repetitive transcranial magnetic stimulation (rTMS), with a positive response in 10 cases. Pain intensity in our group was evaluated with the visual analogue scale (VAS) one month before and three months after MCS implantation. Improvement on the VAS was reported in the whole group of patients (p < 0.001). The best results were reported in the NFP group (p < 0.001) while the worst ones were noted in the DP group (p = 0.04). Anamnesis duration positively correlated with outcome. Infection forced the authors to permanently remove the system in one case. There were no other complications in the group. Minimally invasive, safe neuromodulative treatment with MCS permits neuropathic pain control with good efficacy. The type of neuropathic pain might be a prognostic factor.
- 1 January 2012
- Published by VM Media Group sp. z o.o in Neurologia i Neurochirurgia Polska
- Vol. 46 (5) , 428-435
Motor cortex stimulation in the treatment of neuropathic pain
Despite the rapid development of neuropharmacotherapy, medical treatment of neuropathic pain (NP) still constitutes a significant socioeconomic problem. The authors herein present a group of patients treated with motor cortex stimulation (MCS) for NP of various types and aetiologies. Our cohort included 12 female and 11 male NP patients aged 53 ± 16 treated with MCS. Eleven patients were diagnosed with neuropathic facial pain (NFP), 8 with hemi-body neuropathic pain (HNP), and 4 with deafferentation pain (DP). Prior to surgery, 16 out of 23 patients were treated with repetitive transcranial magnetic stimulation (rTMS), with a positive response in 10 cases. Pain intensity in our group was evaluated with the visual analogue scale (VAS) one month before and three months after MCS implantation. Improvement on the VAS was reported in the whole group of patients (p < 0.001). The best results were reported in the NFP group (p < 0.001) while the worst ones were noted in the DP group (p = 0.04). Anamnesis duration positively correlated with outcome. Infection forced the authors to permanently remove the system in one case. There were no other complications in the group. Minimally invasive, safe neuromodulative treatment with MCS permits neuropathic pain control with good efficacy. The type of neuropathic pain might be a prognostic factor.
- 1 January 2012
- Published by VM Media Group sp. z o.o in Neurologia i Neurochirurgia Polska
- Vol. 46 (4) , 326-332
Statistical analysis of the intracranial procedures in Poland in 2008–2009
Quantitative and qualitative analysis of neurosurgical procedures provides important data for assessment of the development and trends in the field of neurosurgery. The authors present statistical data on intracranial procedures (IPs) performed in Poland in 2008-2009. Data on IPs come from reports of the National Health Fund, grouped according to the system of Diagnosis-Related Groups, group A - nervous system diseases. Data concerning the year 2009 include all IPs performed in Poland. Data from the second half of 2008 to 2009 (18 months) come from 35 neurosurgical centers in Poland, divided by provinces. We analyzed the number of IPs, the cost of procedures, duration of hospitalization and deaths. 20 849 IPs were performed in Poland in 2009. The most common procedure was A12 (6807; 32.65%), and the rarest was A04 (96; 0.46%). The annual cost of all IPs was 228 599 956 PLN. Average cost of the procedure ranged from 1578 PLN (A14) to 47 940 PLN (A03). Duration of the hospitalization ranged between 3 days (A14) and 12 days (A12). The highest percentage of deaths was reported for A01 (n = 1050, 19.06%). Reports from 35 neurosurgical centers in the second half of 2008 and 2009 showed the highest number of IPs per 100 000 population in Kujawsko-Pomorskie (93) and the lowest in Wielkopolskie (27) and Podkarpackie (27). The highest number of IPs (1669) was performed in neurosurgical center M1 (Małopolskie), and the lowest (99) in W1 (Wielkopolskie). A significant disparity in the number of IPs performed in different centers in Poland was observed.
- 1 January 2012
- Published by VM Media Group sp. z o.o in Neurologia i Neurochirurgia Polska
- Vol. 46 (4) , 326-332
Statistical analysis of the intracranial procedures in Poland in 2008–2009
Quantitative and qualitative analysis of neurosurgical procedures provides important data for assessment of the development and trends in the field of neurosurgery. The authors present statistical data on intracranial procedures (IPs) performed in Poland in 2008-2009. Data on IPs come from reports of the National Health Fund, grouped according to the system of Diagnosis-Related Groups, group A - nervous system diseases. Data concerning the year 2009 include all IPs performed in Poland. Data from the second half of 2008 to 2009 (18 months) come from 35 neurosurgical centers in Poland, divided by provinces. We analyzed the number of IPs, the cost of procedures, duration of hospitalization and deaths. 20 849 IPs were performed in Poland in 2009. The most common procedure was A12 (6807; 32.65%), and the rarest was A04 (96; 0.46%). The annual cost of all IPs was 228 599 956 PLN. Average cost of the procedure ranged from 1578 PLN (A14) to 47 940 PLN (A03). Duration of the hospitalization ranged between 3 days (A14) and 12 days (A12). The highest percentage of deaths was reported for A01 (n = 1050, 19.06%). Reports from 35 neurosurgical centers in the second half of 2008 and 2009 showed the highest number of IPs per 100 000 population in Kujawsko-Pomorskie (93) and the lowest in Wielkopolskie (27) and Podkarpackie (27). The highest number of IPs (1669) was performed in neurosurgical center M1 (Małopolskie), and the lowest (99) in W1 (Wielkopolskie). A significant disparity in the number of IPs performed in different centers in Poland was observed.
- 1 April 2007
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 17 (S 01) , A322
Chordomas of the Clivus and Craniocervical Junction: Results and Follow-Up after Surgical Resection
Chordomas are rare tumors derived from the notochord remnants. According to their localization and invasiveness, their surgical treatment is still a challenge. The purpose of our study was to evaluate the outcome of 18 patients with large clival chordomas treated surgically in M. Sklodowska Memorial Cancer Center between 1999 and 2006. All the patients had a pathologically confirmed diagnosis of chordoma. For the present analysis the cases of large tumors (maximum diameter > 50 mm) located at the clivus and/or craniocervical junction were included. Different skull base approaches (fronto-orbitozygomatic, transmaxillary, suboccipital-transcondylar, trans-sphenoidal, and the transbasal) were used for the tumor removal. The follow-up period ranged from 3 to 82 months (median, 40 mos). Gross total resection was accomplished in 5 patients (27.5%). Subtotal removal was achieved in 8 patients (45%), and partial removal in 5 patients (27.5%). Adjuvant therapy consisted of postoperative conventional radiation therapy given to 14 patients and proton-photon beam therapy given to 3 patients (22%). There was one death related to surgical treatment. The most common surgical complications were cranial nerve deficits and cerebrospinal fluid leak. At the present follow-up review (median, 40 mos) 13 patients (77%) were still alive, and 4 patients (23%) had died of chordoma recurrence. The analysis of factors influencing the prognosis indicate that the radical resection with the use of skull base approaches is the principal factor favoring better outcome.
- 1 April 2007
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 17 (S 01) , A322
Chordomas of the Clivus and Craniocervical Junction: Results and Follow-Up after Surgical Resection
Chordomas are rare tumors derived from the notochord remnants. According to their localization and invasiveness, their surgical treatment is still a challenge. The purpose of our study was to evaluate the outcome of 18 patients with large clival chordomas treated surgically in M. Sklodowska Memorial Cancer Center between 1999 and 2006. All the patients had a pathologically confirmed diagnosis of chordoma. For the present analysis the cases of large tumors (maximum diameter > 50 mm) located at the clivus and/or craniocervical junction were included. Different skull base approaches (fronto-orbitozygomatic, transmaxillary, suboccipital-transcondylar, trans-sphenoidal, and the transbasal) were used for the tumor removal. The follow-up period ranged from 3 to 82 months (median, 40 mos). Gross total resection was accomplished in 5 patients (27.5%). Subtotal removal was achieved in 8 patients (45%), and partial removal in 5 patients (27.5%). Adjuvant therapy consisted of postoperative conventional radiation therapy given to 14 patients and proton-photon beam therapy given to 3 patients (22%). There was one death related to surgical treatment. The most common surgical complications were cranial nerve deficits and cerebrospinal fluid leak. At the present follow-up review (median, 40 mos) 13 patients (77%) were still alive, and 4 patients (23%) had died of chordoma recurrence. The analysis of factors influencing the prognosis indicate that the radical resection with the use of skull base approaches is the principal factor favoring better outcome.
- 1 January 2004
- Vol. 42 (2) , 67-73
The concentration of thyroid hormones and activities of iodothyronine deiodinases are altered in human brain gliomas.
We have determined the cellular concentration of thyroxine (T4) and triiodothyronine (T3) and the activities of two brain iodothyronine deiodinases, type II (5'-D2) and type III (5-D3), in two types of tissues --tumour (26) and non-tumour (5), derived either from human gliomas with various histological malignancies or from non-tumoural surrounding brain tissue. As it has been established, all patients before the surgery had the Non-Thyroidal Illness Syndrome (NTIS). The concentration of serum T3 was therefore significantly decreased in all the examined patients. It was over 2.5 times lower than that before surgery and 4.0 times lower at surgery than that seen in healthy controls. The serum concentration of T4 was found to be below normal range in 4/26 cases and in low levels of normal range in 6/26 cases, whereas TSH serum concentration in all patients was within normal range. The concentrations of T3 and T4 (expressed as pg of hormone/mg tissues protein) in 22/26 brain tissue samples were significantly lower in gliomas than in 5 non-tumoural brain tissue samples. As expected, the alternation in brain 5'D II activity in gliomas was seen in most cases with astrocytomas (5/8 cases), gliosarcomas (8/8 cases) and glioblastoma multiforme (10/10 cases). In general, the mean enzyme activity in tumour tissue was significantly higher than that found in non-tumoural tissue of human brain (21.79 fmol of newly generated T3/h/mg of protein vs. 4.88 fmol of T3/h/mg protein, respectively). The highest 5'D2 activity with a range from 10.82 to 45.96 (mean 23.61 fmol T3/h/mg protein) was found in gliosarcomas. The activity of 5-D3 was increased (in 8/8 cases of gliosarcoma and in 9/10 cases of glioblastoma multiforme) or decreased (in 3/3 cases of astrocytoma II, 5/5 cases of astrocytoma III) when compared to mean activity of this enzyme found in non-tumoural brain tissue. In summary, our results suggest that the concentration of brain iodothyronines and metabolism of thyroid hormones in the examined human brain tumours are altered. These changes may be related to malignant progression.
- 1 January 2004
- Vol. 42 (2) , 67-73
The concentration of thyroid hormones and activities of iodothyronine deiodinases are altered in human brain gliomas.
We have determined the cellular concentration of thyroxine (T4) and triiodothyronine (T3) and the activities of two brain iodothyronine deiodinases, type II (5'-D2) and type III (5-D3), in two types of tissues --tumour (26) and non-tumour (5), derived either from human gliomas with various histological malignancies or from non-tumoural surrounding brain tissue. As it has been established, all patients before the surgery had the Non-Thyroidal Illness Syndrome (NTIS). The concentration of serum T3 was therefore significantly decreased in all the examined patients. It was over 2.5 times lower than that before surgery and 4.0 times lower at surgery than that seen in healthy controls. The serum concentration of T4 was found to be below normal range in 4/26 cases and in low levels of normal range in 6/26 cases, whereas TSH serum concentration in all patients was within normal range. The concentrations of T3 and T4 (expressed as pg of hormone/mg tissues protein) in 22/26 brain tissue samples were significantly lower in gliomas than in 5 non-tumoural brain tissue samples. As expected, the alternation in brain 5'D II activity in gliomas was seen in most cases with astrocytomas (5/8 cases), gliosarcomas (8/8 cases) and glioblastoma multiforme (10/10 cases). In general, the mean enzyme activity in tumour tissue was significantly higher than that found in non-tumoural tissue of human brain (21.79 fmol of newly generated T3/h/mg of protein vs. 4.88 fmol of T3/h/mg protein, respectively). The highest 5'D2 activity with a range from 10.82 to 45.96 (mean 23.61 fmol T3/h/mg protein) was found in gliosarcomas. The activity of 5-D3 was increased (in 8/8 cases of gliosarcoma and in 9/10 cases of glioblastoma multiforme) or decreased (in 3/3 cases of astrocytoma II, 5/5 cases of astrocytoma III) when compared to mean activity of this enzyme found in non-tumoural brain tissue. In summary, our results suggest that the concentration of brain iodothyronines and metabolism of thyroid hormones in the examined human brain tumours are altered. These changes may be related to malignant progression.
- 29 April 2003
- Vol. 36 (6) , 1121
[Skull base surgery techniques in the treatment of pituitary adenomas].
The giant pituitary adenoma surgery remains a real challenge to any neurosurgeon. Despite an extensive development of transsphenoidal techniques, open craniotomy procedures still are required in 5-10% of all cases with pituitary adenoma. The skull base surgery techniques not only allow to minimize the surgery-related trauma of the brain, but also improve the access to the operating field. In the years 1998-2001 the authors operated on the total of 395 pituitary adenoma patients, mostly using the transsphenoidal approach (320 cases), with skull base surgery techniques applied in 75 cases (i.e. in 19% of all patients)--in 67 patients the transbasal-subfrontal approach was applied, and in 2 cases--lateral rhinotomy. There were two indications to the transbasal-subfrontal approach: a large size of the tumor causing visual disturbances, and extension of the adenoma to adherent anatomical spaces. In this group of patients the total removal of the tumour was achieved in 88% of cases. In the remaining patients remnants of the tumor were left in the cavernous sinuses. The skull base surgery techniques are most useful in the treatment of selected patients with pituitary adenoma.
- 29 April 2003
- Vol. 36 (6) , 1121
[Skull base surgery techniques in the treatment of pituitary adenomas].
The giant pituitary adenoma surgery remains a real challenge to any neurosurgeon. Despite an extensive development of transsphenoidal techniques, open craniotomy procedures still are required in 5-10% of all cases with pituitary adenoma. The skull base surgery techniques not only allow to minimize the surgery-related trauma of the brain, but also improve the access to the operating field. In the years 1998-2001 the authors operated on the total of 395 pituitary adenoma patients, mostly using the transsphenoidal approach (320 cases), with skull base surgery techniques applied in 75 cases (i.e. in 19% of all patients)--in 67 patients the transbasal-subfrontal approach was applied, and in 2 cases--lateral rhinotomy. There were two indications to the transbasal-subfrontal approach: a large size of the tumor causing visual disturbances, and extension of the adenoma to adherent anatomical spaces. In this group of patients the total removal of the tumour was achieved in 88% of cases. In the remaining patients remnants of the tumor were left in the cavernous sinuses. The skull base surgery techniques are most useful in the treatment of selected patients with pituitary adenoma.